According to Vision Research Reports, the HLA typing market was surpassed at USD 1.3 billion in 2021 and is expected to hit around USD 2.11 billion by 2030, growing at a CAGR of 5.53% from 2022 to 2030.
According to Vision Research Reports, the HLA typing market was surpassed at USD 1.3 billion in 2021 and is expected to hit around USD 2.11 billion by 2030, growing at a CAGR of 5.53% from 2022 to 2030.
HLA also termed human leukocyte antigen typing is a type of genetic test that is also sometimes referred to as tissue typing. These are the proteins (markers) found in the cells of the body. HLA are the genes of MHS for protein-coding to distinguish between self and non-self. It helps to identify the bacteria and viruses that attack the body or other infections. The test is performed to evaluate whether a person is safe to donate bone marrow, organ, or cord blood for transplant or tissue transplant. For the test, the blood sample or the swab inside the cheeks is required of both the donor and recipient. There are three types of HLA namely HLA-A, HLA-B, HLA-DR.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39766
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 1.3 billion |
| Revenue Forecast by 2030 | USD 2.11 billion |
| Growth rate from 2022 to 2030 | CAGR of 5.53% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Product, Technique, Application, End user, Region |
| Companies Covered | Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Luminex Corporation, Qiagen N.V., Omixon Inc., Genome Diagnostics B.V., Illumina Inc., Immucor Inc., TBG Diagnostics Limited, Fujirebio Holdings Inc., Dickinson and Company, Beckton, Takara Bio Inc., F. HOFFMAN-LA ROCHE LIMITED, Pacific Biosciences, inno-Train Diagnostik GmbH among others |
Based on the health condition there are two types of transplants -
- Stem-cell Transplant: Used to treat cancer and genetic blood disorders. Here bone marrow or peripheral blood is used for the transplant. Example - Stem cell transplant to treat sickle cell disease.
- Solid-organ Transplant: The conditions like trauma, toxins, genetic illness, and autoimmune disease can lead to organ damage. So transplants for the liver, kidney, and lungs can be done in these cases.
The prevalence of genetic disorders, autoimmune diseases, and chronic diseases has increased. The procedures of organ transplant and bone marrow donation have increased to cure these disorders. There is an increasing prevalence of diseases like sickle cell disease, and thalassemia which boosts the market. HLA typing has a wide range of applications in renal transplant, platelet transfusion, paternity testing, and diagnosis of ankylosing spondylitis. It can also be used to diagnose diseases like narcolepsy, rheumatoid arthritis, stem cell transplant, and Behcet’s disease which paves the way to accelerate the market for HLA typing. Recently in May 2022, a detection kit named DiscoverSeries HLAB*27 for in vitro diagnosis of Ankylosing spondylitis was launched by Mylab Discovery Solutions. The demand for molecular diagnostic tests has increased due to their promising results. So there is increasing consumer demand for HLA typing tests which drives the market. But the gene sequencing tests and molecular tests are costly which thwart the adoption and market growth to an extent.
The market is segmented based on the product, technique, application, end-user, and region. The product segment is divided into instruments, reagents and consumables, software and services. The technique segment is divided into molecular assay, sequenced based molecular assay, and non-molecular assay. The application segment is divided into diagnostic applications and research applications. The diagnostic application can be further sub-segmented into donor-recipient cross-matching, infectious disease testing, cancer diagnosis and prevention, transfusion therapy. The end-user segment is divided into hospital and transplant centers, research laboratories, and independent reference laboratories. The region segment is further segmented by North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
As per the regional analysis research, North America holds the market due to the rising genetic disorders. So there are advanced healthcare and research facilities available. Moreover, the government and companies are focused on the advancements in organ transplant which accelerates the HLA typing market. Asia-Pacific region also holds a significant market due to the improved infrastructure of the healthcare facilities, better healthcare reimbursement policies, and better economic growth which positively boosts the market. Along with this skilled professionals and availability of the transplant hospitals, and laboratories with advanced technologies will boost the market.
Key Market Trends
Hospital Segment is Expected to Exhibhit a Significant Market Growth in the HLA Typing Market
The hospital segment is expected to grow at a significant rate in the HLA typing market, due to the increasing number of organ transplants and the developing infrastructure of hospitals in terms of advanced devices and equipment. For instance, Cambridge University Hospital provides HLA typing tests for solid organ transplantation, hematopoietic stem cell transplantation, and also for the diagnosis of various diseases, such as rheumatoid arthritis, narcolepsy, behçet’s disease, among others.
Furthermore, according to the organdonor.gov updated in March 2022, the number of organ donors and transplantations took place in 2021 for various organs such as kidneys, liver and heart in the United States include, 90,483, 11,891, 3,502 and 24,670, 9,236 and 3,817 respectively. Such a huge number of organ transplantation that takes place in hospitals will therefore lead to increased adoption of HLA typing tests in the hospitals, thereby driving this segment growth.
In addition, rising initiatives by the hospitals for conduction of camps and bone marrow donation programs will further drive the growth of this segment. For instance, in May 2022, on the occasion of World Thalassemia Day, Aster Hospitals held a stem-cell donor drive in collaboration with I Love To Care (India) Charitable Trust and DKMS-BMST Foundation India to increase awareness and provide hope for children with thalassemia. The drive was organized to encourage people to come forward and register as stem cell donors. Such initiatives will lead to increased adoption of HLA testing in the hospitals to match the bone marrow of patients, driving this segment growth.
Therefore, owing to the above mentioned factors, the hospital segment is expected to register a significant growth over the forecast period.
Key Players
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories Inc.
- Luminex Corporation
- Qiagen N.V.
- Omixon Inc.
- Genome Diagnostics B.V.
- Illumina Inc.
- Immucor Inc.
- TBG Diagnostics Limited
- Fujirebio Holdings Inc.
- Dickinson and Company
- Beckton
- Takara Bio Inc.
- F. HOFFMAN-LA ROCHE LIMITED
- Pacific Biosciences
- inno-Train Diagnostik GmbH
- others
Market Segmentation
- By Product
- Instruments
- Reagents and Consumables
- Software and Services
- By Technique
- Molecular Assay
- Sequenced-based Molecular Assay
- Non-Molecular Assay
- By Application
- Diagnostic Application
- Research Application
- By End user
- Hospitals and Transplant Centers
- Research Laboratories
- Independent Reference Laboratories
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39766
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/